Introduction
Venous thromboembolism (VTE) is a multicausal disease in which genetic and acquired risk factors interact dynamically, affecting approximately 1:1000 people per year. 1 During the past decade, knowledge regarding the etiology of venous thrombosis has advanced with the discovery of several factors that contribute to the incidence of thrombosis, particularly the role of coagulation abnormalities. 2, 3 Studies examining the epidemiology of VTE have historically centered on developed countries, limiting the delineation of risk factors predominantly to the Caucasian population. In this group, Increased coagulation factor levels have been demonstrated to be a risk factor for venous thromboembolism in patients of Caucasian origin. Coagulation factors, hereditary thrombophilia, and ABO blood group were evaluated for venous thrombosis risk in a heterogeneous Brazilian population consisting of 122 women and 53 men, with a median age of 36 years (range 13-63), matched to a control group by age, sex, and ethnicity. Increased levels of factor VIII (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.6-6.0), von Willebrand factor (OR, 2.8; 95% CI, 1.4-5.4), non-O blood group (OR, 2.1; 95% CI, 1.3-3.4), and thrombophilia (OR, 3.4; 95% CI, 1.6-7.1) emerged as independent risk factors for venous thromboembolism. The interaction of high levels of factor IX and factor XI with other independent variables increased the potential for thrombosis synergistically. Therefore, the ability of identifying underlying thrombophilia risk factors in our population was enhanced by the inclusion of these factors in the prothrombotic laboratory workup.
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Recent genomic surveys have shown that susceptible alleles for common chronic diseases are located on common haplotypes and that these alleles must be shared by members of all populations. Brazil has one of the most heterogeneous populations, characterized by a genetic admixture of Europeans, African immigrants, and native indigenous descendants. Thus, the genetic complexity of haplotypes in a heterogeneous population under similar environmental risk factors may provide an ideal setting for evaluating relevant contributions from individual factors.
In this article, we report findings on a casecontrol study to assess the role of clotting factor levels and inherited thrombophilia in a series of Brazilian patients with venous thrombosis. Our data suggest that sustained elevated levels of clotting factors are the most common independent risk factors for venous thrombosis.
Materials and Methods
This case-control study included patients with an objective first episode of VTE who were matched to controls by age, sex, and ethnicity. We consecutively recruited patients from the Anticoagulation Clinic of the State University of Campinas-Brazil during the period of January 2003 to January 2005. The study population included a total of 175 (62.5%) patients out of 280 patients with VTE. We excluded all patients (n = 105) aged 70 years or more; those with a known malignant disorder; and those with liver, renal, or autoimmune diseases, such as those with a diagnosis of antiphospholipid antibody syndrome. For all patients, plasma samples were collected within a minimum of 3 months following their acute thrombosis. Controls consisted of patients' friends from the same geographic area with no personal or familial history of venous thrombosis. At the time of plasma sampling, all patients and controls were off any medication, and none of the female subjects were pregnant. The diagnosis of deep venous thrombosis of lower limbs and pulmonary embolism were confirmed by duplex ultrasonography and ventilation-perfusion scanning, respectively, whereas the thrombosis of the portal venous system or cerebral veins were confirmed by venous computerized tomography, venous magnetic resonance imaging, or angiography. It is important to highlight that the Brazilian population is an admixture of Caucasians, African immigrants, and native indigenous descendants. The determination of ethnicity was based on ascendance up to the third generation and physical characteristics. Although the study had tried to establish a division of patients and controls according to race, it is important to emphasize that the Brazilian population is a genetic admixture of 3 racial components mentioned above. All procedures were reviewed and approved by the Institutional Review Board of the State University of Campinas, and written informed consent was obtained from all the participants.
Plasma levels of protein C, protein S, and antithrombin and the presence of lupus anticoagulant and/or anticardiolipin antibody were determined as described. 13 Genomic DNA was extracted cellular pellets for the determination of factor V Leiden (FV Leiden) and FII G20210A mutations by polymerase chain reaction-based assay, as previously reported. 13 ABO phenotypes were determined by agglutination and adsorption-elution tests using monoclonal and polyclonal anti-A, anti-B, and anti-AB antibodies (DiaMed SA, Cressier sur Morat, Switzerland, or DiaMed Latino América, Lagoa Santa, Brazil).
Clotting activity assays for FVII, FVIII, FIX, FX, and FXI were determined by 1-stage assay using a pool of plasma deficient for a specific clotting factor (BioMérieux, Durham, NC). The tests were performed in duplicate on a fully automated coagulation analyzer (Koagulab 32-S, Diagnostica Stago, Asnieres-sur-Seine, France). von Willebrand factor (vWF) levels were measured using enzyme-linked immunosorbent assay with rabbit monoclonal antiserum (Dako, Glostrup, Denmark). Fibrinogen concentrations were determined according to the Clauss method using thrombin (Fibriquik; BioMérieux).
C-reactive protein (CRP) levels were determined by a nephelometric method (Dade Behring, Marburg, Germany). When CRP values were higher than 1 mg/dL, we requested an additional blood sample. All patients with persistent high values of CRP were excluded from the study. Clotting factor levels were considered solely in the presence of normal CRP levels. To further confirm if the increased levels represented a persistent finding, additional blood samples were obtained 6 months later from patients and controls with increased coagulation factors.
Statistical Analysis
The quantitative variables age and coagulation factor levels were expressed as mean and standard deviation, and comparison between the groups was performed by the Mann-Whitney test. A P value < .05 was considered as statistically significant.
The association between variables of interest (coagulation factors, blood group, and classical hereditary thrombophilia) and risk for VTE was found by calculating the odds ratio (OR) with 95% confidence interval (CI). The hereditary thrombophilias considered were FV Leiden and FII G20210A mutations and deficiency of protein C, protein S, and antithrombin. The cutoff point used for coagulation factors was the 90th percentile measured in controls. Blood group (O and non-O) and hereditary thrombophilia (presence or absence) were entered as dichotomized variables.
The univariate logistic regression model used included fibrinogen, FVII, FVIII, vWF, FIX, FX, FXI, ABO blood group, and thrombophilia. Subsequently, a conditional logistic model was used that included only those coagulation factors considered risk factors in univariate analysis, adjusted for each of the following confounding variables: CRP (cutoff point of 90th percentile measured in controls), thrombophilia, and other coagulation factors. A second stage was carried out using a multivariate model, according to stepwise selection criteria, including all the variables.
For coagulation factors considered independent risk factors, the attributed population risk, derived from the OR and the prevalence of the risk factor in the population, was calculated. 14 Statistical analysis was performed using the SAS System for Windows, version 8.02.
Results
The study group consisted of 122 women and 53 men, with a mean age of 36.5 years (standard deviation = 11). Seventy-five patients (42.9%) were classified as non-Caucasians. In 153 (76.5%) patients, the lower limbs were the site of thrombosis. In 75 (37.5%) patients, the episode of thrombosis was spontaneous, and in 125 (62.5%) patients, the disease was secondary to an acquired risk factor (surgery, immobilization, oral contraceptives, pregnancy, and puerperium). Hereditary thrombophilia was diagnosed in 35 (20%) patients. FV Leiden mutation, Protein C deficiency, and FII G20210A mutation occurred in 13 (7.5%), 11 (6.3%), and 8 (4.6%) patients, respectively. The median time between thrombosis and venipuncture was 20 months (range, 6 to 110 months). CRP levels were elevated in 10 patients, and additional samples were collected to further confirm persistent high levels in 4 out of 10 patients. These patients were then excluded from the study.
ABO Blood Groups and Levels of FVIII, FIX, FXI, and vWF Influence the Risk for VTE
We determined that FVIII and vWF levels were significantly higher in individuals (both patients and controls) of non-O blood group than in individuals of O blood group, as previously reported in the literature. 7, 9 Non-O blood group conferred a 3-fold (OR, 3.0; 95% CI, 1.9-4.6) thrombotic risk when compared with O blood group.
The mean levels of fibrinogen, FVIII, FIX, FXI, and vWF were significantly higher in patients (306.1 mg/dL, 191 IU/dL, 129.6 IU/dL, 128.5 IU/dL, and 162.6 IU/dL, respectively) than in controls (291.5 mg/dL, 135.7 IU/dL, 113 IU/dL, 108.2 IU/dL, and 111.9 IU/dL, respectively; P < .05). The means for FVII and FX did not differ between patients (108.8 and 111.7 IU/dL, respectively) and controls (105 and 112.6 IU/dL, respectively).
The 90th percentiles of fibrinogen, FVII, FVIII, FIX, FX, FXI, and vWF levels in the control group were 379 mg/dL, 139 IU/dL, 212 IU/dL, 153.8 IU/dL, 133 IU/dL, 150.5 IU/dL, and 172.8 IU/dL, respectively. Individuals with FVIII, FIX, vWF, and FXI levels above the 90th percentile had a higher VTE risk, as compared with those at the lower cutoff point. There was no association between fibrinogen, FVII, and FX levels and risk of thrombosis (Table 1) .
Further calculations including only those variables considered risk factors in a univariate analysis revealed that after an adjustment for hereditary thrombophilia and CRP, the risk conferred by FVIII (OR, 5.8; 95% CI, 3.2-10.5), vWF (OR, 4.8; 95% CI, 2.6-8.9), and ABO blood group (OR, 3.2; 95% CI, 2.0-5.1) remained unchanged. The same result was obtained when FVIII, vWF, and ABO blood group were separately adjusted for FIX and FXI.
Increased Levels of FIX or FXI Are Not Independent Risk Factors for Venous Thrombosis
The OR in the univariate analysis, considering the 90th percentile of FIX, was 2.4 (95% CI, 1.3-4.4; P = .004). When adjusted for CRP levels and thrombophilia, the risk remained unchanged (OR, 2.4; 95% CI, 1.3-4.5; P = .05). The risk remained when adjusted for FXI (OR, 2.0; 95% CI, 1.1-3.9; P = .02), ABO blood group (OR, 1.8; 95% CI, 1.0-3.5; P = .04), and vWF (OR, 1.8; 95% CI, 1.0-3.5; P = .05). The risk conferred to FIX disappeared after adjusting for FVIII (OR, 1.6; 95% CI, 0.8-3.1; P = .15). When all these variables were adjusted, VTE risk for FIX exceeding the 90th percentile was 1.4 (95% CI, 0.7-2.9; P = .3). Similarly, the OR associated with FXI activity over the 90th percentile was 2.1 (95% CI, 1.1-4.0; P = .01). When adjusted for CRP levels (OR, 2.4; 95% CI, 1.3-4.5; P = .05), thrombophilia (OR, 1.9; 95% CI, 1.0-3.7; P = .03), or vWF (OR, 2.0; 95% CI, 1.0-3.8; P = .02), the risk remained. When adjusted for FIX (OR, 1.7; 95% CI, 0.9-3.3; P = .07), FVIII (OR, 1.5; 95% CI, 0.7-2.9; P = .2), or ABO blood group (OR, 1.6; 95% CI, 0.8-3.1; P = .1), the risk disappeared. When all these variables were adjusted, the VTE risk for FXI exceeding the 90th percentile was 1.2 (95% CI, 0.5-2.0; P = .5).
High Levels of FVIII, vWF, Inherited Thrombophilia, and Non-O Blood Group Are Independent Risk Factors for Venous Thrombosis
Analysis of all these variables by stepwise selection criteria showed non-O blood group, high levels of FVIII and vWF, and inherited thrombophilia as independent risk factors for venous thrombosis ( Table 1 ). The population-attributable risk conferred by high levels of FVIII and vWF was 30% and 27%, respectively. High levels of FVIII, vWF, and non-O blood group conferred the highest risks for VTE, when associated to elevation of FIX or FXI levels (Tables 2 and 3) .
When the analysis was performed by dividing the participants into 2 groups-Caucasians and non-Caucasians-it was found that whereas high levels of FVIII, vWF, and non-O blood group were related to thrombotic risk in both groups, FIX and FXI were only associated to risk in the former group (Table 4 ).
Discussion
Over the past decades, it has become clear that the early assumption that venous thrombosis was less prevalent among non-Caucasians was erroneous. Growing clinical evidence demonstrates that these individuals not only present venous thrombosis comparable with the Caucasian rates but also that the prognosis seems to be worse. 15, 16 Therefore, the identification of risk factors for venous thrombosis is anticipated as an important public health care issue for developing countries. Commonly, early epidemiological and molecular studies on thrombophilia risk factors are carried out among Caucasian populations and then further tested among several groups worldwide. Interestingly, the results revealed a highly heterogeneous impact of a given risk factor in disease phenotype. In addition to ethnicity, there are several reasons for these discrepancies, which range from patient selection to the use or nonuse of appropriate laboratory diagnostics and quality of patient follow-up. The identification of FV Leiden and FII G20210A mutations in about 5% to 10% of the general population of Caucasians origin and 1% or less among non-Caucasians provides a clear example of the limitation of these studies. 4 Despite the low prevalence of hereditary thrombophilia among descendents of African immigrants with VTE, a familial history of the disease is equal for African descendents and Caucasians. 17 As the heterogeneous Brazilian population has a good percentage of African descendents, we believe that it would be appropriate to search for new prothrombotic genetic risk factors in these individuals.
Specifically, we were interested in determining the levels of procoagulant clotting factors as a marker for venous thrombosis in this group of patients. We believe that our study is novel as it is the first to evaluate coagulation factor levels as risk factors for VTE in a heterogeneous population. Circulating plasma levels of clotting factors present a wide range within a determined population and results from both genetic and environmental determinants. More recently, it has been suggested that the expression of proteins involved in coagulation depends on regulatory genes different from those coding for individual coagulation proteins 18 and that these genes may be different across racial groups. 19 Therefore, the potential of coagulation factors in modulating the disease phenotype may most likely vary according to the population analyzed.
Herein, we demonstrated that sustained increased levels of coagulation factors enhance the risk for VTE in a Brazilian population. In the absence of underlying nonspecific inflammatory reactions, high levels of FVIII and vWF increased 3-fold the risk for VTE, which persisted after blood group phenotype correction. The prevalence of individuals with high FVIII levels was higher than that reported among Caucasians 7,8 and similar to those findings among nonadmixed African descendents. 5 In this study, we determined that 212 IU/dL was the appropriate cutoff point to designate FVIII levels as elevated, a value different from the one used for other populations. [7] [8] [9] It is known that levels of FVIII and vWF are influenced by several factors such as sex, age, and ethnicity. 20 Therefore, the definition of an upper reference level must be based on the measurement of coagulation factors in healthy subjects, representative of the study population.
The results of this study emphasize the epidemiological importance of the elevation of these coagulation factors in the development of VTE in this Brazilian population, as about 30% of all cases of the disease were attributable to high levels of FVIII and vWF individually. This value was higher than in Caucasian subjects, in whom the attributable risk to high levels of FVIII was 16%. 21 Together, these data suggest that screening for FVIII and vWF levels may possibly improve the identification of Brazilians having high risk for VTE. We were not able to identify an independent role of FIX and FXI in increased risk for VTE. However, the interaction between high levels of these coagulation factors and other variables resulted in an amplification of thrombotic risk. These data are in contrast to the findings of previous studies involving Caucasians, which demonstrated an independent role of these factors for VTE. 10 Another possible explanation for these conflicting results could be the selection of confounding factors adjusted in a multivariate model, which was different in the present study. The knowledge of the interrelations among coagulation factor levels is relevant in deciding which factors to adjust for in a multivariate model. 18 The heterogeneous ethnicity of our patients could be another factor influencing the results, because when the analyses included only non-Caucasians patients, FIX and FXI were not associated to thrombotic risk.
The mechanisms responsible for increased FVIII levels remain unknown, although family studies have suggested that elevated FVIII levels are genetically determined. 22 Acquired factors such as bacterial and/or parasite infection in asymptomatic patients, dietary habit, or pollution may contribute to increase FVIII levels. Further studies in our population are required to identify genetic and other environmental factors that corroborate the increase in FVIII and vWF levels.
In conclusion, high levels of FVIII, vWF, and non-O blood group emerged as independent risk factors for venous thrombosis among Brazilians. Therefore, the ability of identifying underlying thrombophilia risk factors in our population is enhanced by the inclusion of these factors in the prothrombotic laboratory work. .002 NOTE: VTE = venous thromboembolism; OR = odds ratio; CI = confidence interval; BG = blood group; vWF = von Willebrand factor.
